Committee to Hold Hearing on Trump Administration’s Response to the Drug Crisis

Mar 6, 2019
Press Release

Washington, D.C. (Mar. 6, 2019)—On Thursday, March 7, 2019, the Committee on Oversight and Reform will hold a hearing on “The Trump Administration’s Response to the Drug Crisis.”

WHERE:  2154 Rayburn House Office Building

WHEN:  Thursday, March 7, 2019

TIME:  10:00 a.m.

PURPOSE

The hearing will examine the Office of National Drug Control Policy (ONDCP) during the first two years of the Trump Administration, including the coordination of federal, state, and local responses to the opioid crisis. 

The Committee will also examine ONDCP’s compliance with legislation that reauthorized the agency last year.  The reauthorization was passed as part of the SUPPORT for Patients and Communities Act.  Many of the provisions included in the reauthorization derived from H.R. 5925, the Coordinated Response Through Interagency Strategy and Information Sharing Act (CRISIS Act), which was bipartisan legislation developed by then-Chairman Gowdy and then-Ranking Member Cummings, as well as Reps. Mark Meadows and Gerald Connolly.

 

BACKGROUND

 

 

  • For two years, the Trump Administration had no drug control strategy—even though the Administration was required by law to issue an annual strategy in both 2017 and 2018.

 

  • On January 31, 2019, the Trump Administration finally issued its first National Drug Control Strategy, but it was woefully inadequate and fails to comply with numerous provisions in the law.

 

  • For two years, the Trump Administration had no permanent ONDCP Director.  James Carroll was confirmed on January 2, 2019, but appears to have little experience in drug control policy.

 

 

WITNESSES

The Honorable James W. Carroll, Jr.

Director

Office of National Drug Control Policy

Triana McNeil

Acting Director, Strategic Issues

Government Accountability Office

Mike McDaniel

Director

Houston High Intensity Drug Trafficking Area

 

116th Congress